Selected publications
- Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. European Urology. 2019 Academic Article GET IT
-
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Cancer.
2018
Academic Article
GET IT
Times cited: 20 -
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
European Urology.
2017
Academic Article
GET IT
Times cited: 26 -
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
The Lancet.
2017
Academic Article
GET IT
Times cited: 568 -
Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial.
Journal of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 551 -
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Clinical Genitourinary Cancer.
2014
Review
GET IT
Times cited: 23 -
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials.
European Urology.
2013
Academic Article
GET IT
Times cited: 68